Grail, Inc.(US:GRAL) Prnewswire·2025-10-20 10:30Core Points - GRAIL, Inc. has entered into a securities purchase agreement for a private placement expected to yield gross proceeds of approximately $325.0 million before expenses [1][2][4] - The private placement involves participation from both new and existing institutional investors, including notable firms such as Deep Track Capital and Farallon Capital Management [2] - GRAIL plans to utilize the net proceeds for commercial activities, reimbursement efforts, working capital, and general corporate purposes [2][3] Financial Details - GRAIL will issue and sell 4,639,543 shares of common stock at a price of $70.05 per share, with the private placement expected to close on October 21, 2025, pending customary closing conditions [4][5] - The company anticipates that its cash, cash equivalents, and investments, along with the expected net proceeds from this private placement, will fund operations into 2030 [3] Regulatory Information - The securities sold in this private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the U.S. without an effective registration statement or applicable exemption [6] - GRAIL has granted registration rights to purchasers and will file a registration statement with the SEC for the resale of the shares [6] Company Overview - GRAIL is focused on early cancer detection using next-generation sequencing and advanced machine learning technologies, aiming to alleviate the global burden of cancer [8] - The company is headquartered in Menlo Park, CA, with additional locations in Washington, D.C., North Carolina, and the United Kingdom [8]